<DOC>
	<DOC>NCT02211443</DOC>
	<brief_summary>The purpose of this study is to determine whether SCT200 is safe and tolerant in the treatment of metastatic colorectal cancer</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>aged from 18 to 70 years; having histologically confirmed metastatic colorectal cancer; having experienced previous treatment failures including fluoropyrimidine, irinotecan and oxaliplatine chemotherapy regiment; having determined wildtype KRAS tumor; having to have measurable or nonmeasurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; and expected survival of at least ≥3 months; adequate hematological, renal and liver functions: 1. Hematological function: white blood cell count of &gt;4.0×109/L; absolute neutrophil count of &gt;1.5×109/ L; platelet count of &gt;100×109/L; hemoglobin level of &gt;90.0 g/L; 2. Renal function: serum creatinine level of&lt;1.5×upper limit of normal (ULN); 3. Liver function: total bilirubin level of&lt;1.5×ULN; aspartate amino transferase (AST) and alanine amino transferase (ALT) levels of &lt;1.5×ULN; or &lt;5 × ULN for patients with liver metastases; no other malignancies only if they had following malignancies , which were not required to treat or who had curative resection: cervical carcinoma in situ, the skin basal carcinoma or squamous cell carcinoma, bladder epithelial tumors, or only they had some malignancies requirement only surgical therapy and disease free survival≥5 years; no serious nonmalignant diseases including hypertension, diabetes mellitus, coronary artery disease, and mental disorder. not pregnant; or not lactating; or accepted birth control methods during the study; signed an informed consent form which was approved by the institutional review board of the respective medical center . had received EGFR target treatment including EGFR tyrosine kinase inhibitors(TKI), or anti EGFR monoclonal antibody; having to be at least 4 weeks beyond prior anticancer therapy (including corticosteroid , or nitrosourea or mitomycin within 6 weeks of study entry) or participating in other clinical trial, or have not recovered from significant toxicities of prior therapy; chronic use of medication that could interfere with the assessment of drugrelated toxicities or immunologic activity (high dose prednisone or high dose nonsteroid antiinflammatory medication); had recent major surgery (within 28 days); with symptomatically brain metastases (with the exception of clinically brain metastases stable and of no requirement further treatment); with active infection requirement systemic antibiotics treatment; or serious cardiovascular disease;or with evidence of active hepatitis B or C infection; or with human immunodeficiency virus infection; had acute pulmonary disorder; or interstitial pneumonia; or symptomatically chronic obstructive pulmonary disease (COPD) or with risk factors to COPD; with eye inflammation or infection, or any risk factors who could lead to eye disease; with a history of allergic reaction or protein product allergy including antibodies product; pregnant, or lactating, or not accepted birth control methods including male patients. had a history of alcohol or drugs addiction, or with any risk which may affect the patient's health evaluation or mantle state</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Full human anti-EGFR monoclonal antibody (SCT200) ;</keyword>
	<keyword>metastatic colorectal cancer （mCRC）;</keyword>
	<keyword>Escalating doses ;</keyword>
	<keyword>single dose and multiple doses;</keyword>
	<keyword>safety, tolerability and pharmacokinetics.</keyword>
</DOC>